RAO4ZftZuV

Full identifier: http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40

Assigned to 1 class:

Status

Checking for updates...

Nanopublication

 RAO4ZftZuV comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAO4ZftZuV...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAO4ZftZuV... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T15:17:24.207+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAO4ZftZuV... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAO4ZftZuV... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAO4ZftZuV... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
No Records Found

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)